Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) ...Middle East

FDA's two designations demonstrate KER-0193's potential as a treatment for FXS Follows the successful completion of Phase 1 clinical trial Fragile X syndrome is the most common cause of inherited autism LONDON, May 14, 2025 /PRNewswire/ -- Kaerus Bioscience ("Kaerus" or "the Company"), a...

Read More Details
Finally We wish PressBee provided you with enough information of ( Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) )

Also on site :

• Former student kills 10 people in Austrian high school shooting
• Full interview: Susan Rice
• Hollywood Royal, 35, Makes Jaw-Dropping Confession About Taylor Swift's Rock Icon Ex, 36